Bristol-Myers Squibb Company BMY

What the company does

Bristol-Myers Squibb Company is a large-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $125.6B, based in the USA.

It employs about 32,500 people and has been listed since Jan 01, 1972.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM.

Cheap or expensive? relatively cheap

Its price-to-earnings (P/E) is 13.5 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — relatively cheap.

Revenue is growing 6% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 9.9 — they expect higher earnings.

The average analyst price target is 65.42, 6% above the current price (their view, not ours).

The stock sits at 76% of its one-year range (0% = the low, 100% = the high).

The risks

• • Net debt is 1.4× shareholders' equity — high leverage.
• • Quarterly report in 4 days (2026-10-29) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 26 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Most analysts rate it buy (10 vs 1).
• ✅ Pays a dividend (4.0% a year).

What changed this week

Over the past week the stock rose 2.9% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• The Call Bristol-Myers Squibb Bulls Got Right finance.yahoo.com · 2026-10-25
  What the article says

  If you had been weighing Bristol-Myers Squibb against its looming patent cliffs and the promise of late-stage oncology drugs back in October 2025, the result now looks very different on paper. Holding Bristol-Myers Squibb over the past year would have returned 46.5%, including dividends. The question is simple: faced… source ↗

• Bloomsbury Publishing (LSE:BMY) Stock Faces H1 Results Profit Reset finance.yahoo.com · 2026-10-24
  What the article says

  Bloomsbury Publishing just reported its H1 2027 numbers and the share price closed at £6.25 on 23 October, leaving the stock broadly flat over one month and only slightly higher over three. For a group often treated as a dependable compounder, the latest half shows a different tension. Revenue came in at £151.6m with… source ↗

• Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks finance.yahoo.com · 2026-10-24
  What the article says

  Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst performers in the… source ↗

• Bristol Myers Squibb (BMY) Bets On AI Drug Discovery And Wider Trial Access finance.yahoo.com · 2026-10-24
  What the article says

  Bristol Myers Squibb (NYSE:BMY) has entered multi year AI drug development partnerships with Pathos AI and Tempus AI. The agreement gives Bristol Myers Squibb exclusive access to Pathos AI's discovery platform for neuroscience projects. Tempus AI will provide multi year data licensing that connects real world patient… source ↗

• Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know finance.yahoo.com · 2026-10-23
  What the article says

  In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.48, marking a -2.41% move from the previous day. This move lagged the S&P 500's daily loss of 0.52%. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%. Heading into today, shares of the biopharmaceutical… source ↗

• Sector Update: Healthcare Stocks Fall Late Afternoon finance.yahoo.com · 2026-10-23
  What the article says

  Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index dropping 1.3% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in source ↗

What changed since last week

No material change: same valuation verdict, same risk flags, price moved less than 3%.